Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Dual/triple agonist Mar 04 | 2021Payback for Lilly as Tirzepatide Beats Ozempic in Ph3 SURPASS-2 H2H TrialPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Mar 01 | 2021BI and Gubra Partner for Obesity Drug Development; Diabeloop DBLG1 Integrates with Accu-Chek Insight Pump; Tandem Appoints Jordan Pinsker as VP and Medical DirectorPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA Mar 01 | 2021Viatris Generic Rybelsus in the Pipeline; Viatris 2021 Investor DayPurchase Blast
$599
Posted in: Other, SGLT2i Feb 26 | 2021Thoughts on Sotagliflozin HF Indication after Entresto's PARAGON ApprovalPurchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Other Feb 25 | 2021Novo Invests in Danish Facility for Oral Sema Production; MNKD, PRVB, ICPT, BAYRY, and IONS Q4 '20 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Feb 25 | 2021Lilly Partners with Welldoc for Connected Pen AppPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Feb 24 | 2021Tandem and Teladoc Q4 and FY '20 Earnings UpdatesPurchase Blast
$599
Posted in: Insulin Delivery, Other Feb 23 | 2021Insulet and Esperion Q4 '20 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Feb 23 | 2021Medtronic CY Q4 '20 (FY Q3 '21) Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, SGLT2i Feb 22 | 2021DAPA-CKD filed with EMA; February 22-25 CHMP Agenda; G&L Partners with IDFPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Feb 18 | 2021Biocorp Partners with Health2Sync and SocialDiabetes for Connected Pen IntegrationPurchase Blast
$599
Posted in: Dual/triple agonist Feb 17 | 2021Tirzepatide Continues to Perform; Positive Ph3 SURPASS-3 and SURPASS-5 Topline ResultsPurchase Blast
$599
Posted in: Other Feb 16 | 2021Novartis Wins with Entresto PARAGON-HF FDA ApprovalPurchase Blast
$599
Posted in: Glucose Monitoring, Other Feb 16 | 2021Nemaura Q4 ’20 earnings; MET409 POC Data Published in Journal of HepatologyPurchase Blast
$599
Posted in: Bolus Insulin, Glucagon, Other Feb 12 | 2021Biocon/Viatris Bs-aspart and Xeris RTU Glucagon Receive EC Approval; Poxel Q4 and FY '20 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Other, SGLT2i Feb 11 | 2021AZ, DXCM, and Teva Q4 '20 Earnings Updates; Supersapiens Partners with Ironman; Praluent Patent Litigation Upheld by US Court of Appeals; REGN Evinacumab Approved in US as Evkeeza; Former Novo Exec Hired as CMO for Hepion PharmaPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Feb 09 | 2021Lannett to Develop Bs-aspart; Seraxis Raises $40M in Series C Funding Round; Bayer Submits Finerenone for DKD in ChinaPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other Feb 05 | 2021Novo Q4 '20 Post-earnings Event; Sanofi Capital Markets Day 2021; Sanofi and Regeneron Q4 and FY '20 Earnings UpdatesPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Feb 04 | 2021ViaCyte Initiates Ph2 Encapsulated Cell Therapy Trial in T1DM; Lannett, Merck, Roche, and BD Q4 and FY '20 Earnings Updates; Merck CEO to RetirePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other Feb 03 | 2021Novo Broadens Icodec Ph3 program; CSO to Retire; Novo Q4 and FY ’20 Earnings UpdatePurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
